# US 2024/0254443 A1 · Platelet diagnostic imaging agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254443 A1
- Document ID: US20240254443A1
- Status: Published application
- Kind: A1
- Application number: 18/629,638
- Filed: 2024-04-08
- Published: 2024-08-01
- Earliest claimed: 2019-11-27
- Assignees: Cellphire, Inc.
- Applicants: Cellphire, Inc.
- Inventors: Daniel Allen SHEIK; Keith Andrew MOSKOWITZ
- Web page: https://patentgrep.com/patent/US20240254443A1

## CPC

- C12N 5/0644: {Platelets; Megakaryocytes}
- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A61K 35/19: Platelets; Megacaryocytes
- A61K 49/1857: {the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA}
- A61K 49/1887: {Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix}
- A61K 49/1896: {not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides}
- C12N 2529/00: Culture process characterised by the use of electromagnetic stimulation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are MRI agent-loaded platelets, methods of preparing MRI agent-loaded platelets, and methods of using MRI agent-loaded platelets. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent, a cell penetrating peptide, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

## Claims

### Claim 1

A method of preparing MRI agent-loaded platelets, comprising:
contacting platelets with an MRI agent coupled to a cell penetrating peptide;
and a loading buffer comprising a salt, a base, a loading agent, and optionally at least one organic solvent,
to form the MRI agent-loaded platelets.

### Claim 2

A method of preparing MRI agent-loaded platelets, comprising:
a) providing platelets;
and
b) contacting the platelets with an MRI agent coupled to a cell penetrating peptide;
and a loading buffer comprising a salt, a base, a loading agent, and optionally at least one organic solvent
to form the MRI agent-loaded platelets.

### Claim 3

The method of any one of the preceding claims, wherein the platelets are treated with the MRI agent coupled to a cell penetrating peptide and with the loading buffer sequentially, in either order, or concurrently.

### Claim 4

The method of any one of the preceding claims, wherein the platelets are pooled from a plurality of donors.

### Claim 5

A method of preparing MRI agent-loaded platelets comprising
A) pooling platelets from a plurality of donors; and
B) contacting the platelets from step (A) with an MRI agent coupled to a cell penetrating peptide; and with a loading buffer comprising a salt, a base, a loading agent, and optionally at least one organic solvent, to form the MRI agent-loaded platelets.

### Claim 6

The method of any one of the preceding claims, wherein the loading buffer comprises optionally at least one organic solvent.

### Claim 7

The method of any one of the preceding claims, wherein the loading agent is a monosaccharide or a disaccharide.

### Claim 8

The method of any one of the preceding claims, wherein the loading agent is sucrose, maltose, dextrose, trehalose, glucose, mannose, or xylose.

### Claim 9

The method of any one of the preceding claims, wherein the platelets are isolated prior to a contacting step.

### Claim 10

The method of any one of the preceding claims, wherein the platelets are selected from the group consisting of fresh platelets, stored platelet, and any combination thereof.

### Claim 11

The method of any one of the preceding claims, wherein the MRI agent comprises Gadolinium or a nanoparticle.

### Claim 12

The method of any one of the preceding claims, wherein the cell penetrating peptide is Tat, or a portion thereof.

### Claim 13

The method of any one of the preceding claims, wherein the platelets are loaded with the MRI agent in a period of time of 1 minute to 48 hours.

### Claim 14

The method of any one of the preceding claims, wherein the one or more organic solvents selected from the group consisting of ethanol, acetic acid, acetone, acetonitrile, dimethylformamide, dimethyl sulfoxide, dioxane, methanol, n-propanol, isopropanol, tetrahydrofuran (THF), N-methyl pyrrolidone, dimethylacetamide (DMAC), or combinations thereof.

### Claim 15

The method of any one of the preceding claims, further comprising cold storing, cryopreserving, freeze-drying, thawing, rehydrating, and combinations thereof the MRI agent-loaded platelets.

### Claim 16 (depends on 15)

The method of claim 15, wherein the drying step comprises freeze-drying the MRI agent-loaded platelets.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, further comprising rehydrating the MRI agent-loaded platelets obtained from the drying step.

### Claim 18

MRI agent-loaded platelets prepared by the method of any one of the preceding claims.

### Claim 19 (depends on 18)

MRI agent-loaded platelets prepared by a method comprising rehydrating the MRI agent-loaded platelets of claim 18.

### Claim 20

The method of any one of the preceding claims, wherein the method does not comprise contacting the platelets with an organic solvent.

### Claim 21

The method of any one of the preceding claims, wherein the method comprises optionally contacting the platelets with Prostaglandin E1.

### Claim 22

The method of any one of the preceding claims, wherein the method comprises optionally contacting the platelets with a glycoprotein IIb/IIIa inhibitor.
